In the new Goosebumps: The Vanishing trailer, dad and divorcee Anthony (played by David Schwimmer) has one rule for his twins spending a summer in his Gravesend, Brooklyn, home: Stay out of the ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. At the same time ...

Amgen Inc.'s Q3 earnings — due 30th October -are unlikely to be a major upside catalyst due to tricky comparisons, increased R&D spending, and transitional phase challenges. Key patents expiring ...

Amgen is posting strong growth across its diversified-medicines portfolio. A new weight-loss drug candidate could be a game-changer for the company. Trading at 17 times earnings, the stock offers ...

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

Also Read: Amgen/AstraZeneca’s Asthma Drug Tezspire Vs. Sanofi/Regeneron’s Blockbuster Dupixent – Analyst Gives His Pick WAYPOINT is a randomized, double-blind trial that evaluated the ...

Bestselling author David Baldacci will be speaking on Nov. 18 at the Canton Palace Theatre as part of a Stark Library event. The prolific author will be releasing a new book in "The 6:20 Man ...

THOUSAND OAKS, Calif., Oct. 25, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024. The ...

To enhance operational efficiency, accuracy and compliance across its highly regulated and complex workflows, leading biopharmaceutical company Amgen Inc. has kickstarted its fully automated dream ...

Damiano David, the hearthrob Italian musician and Måneskin frontman, is teasing his first solo project, an album with a 2025 release date, one song and video, at a time. September’s reveal was ...

Oct 22 (Reuters) - Amgen (AMGN.O), opens new tab will launch its biosimilar version of Regeneron's (REGN.O), opens new tab blockbuster eye care drug Eylea following a U.S. appeals court ruling in ...

Bernstein started coverage of Eli Lilly (NYSE:LLY), Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) with outperform ratings. The investment firm said its bullish ratings on Gilead and Amgen ...